Keybanc maintains Tenet Healthcare at Overweight, raises price target to $300 from $270

Keybanc kept its Overweight rating on Tenet Healthcare and raised its price target to $300 from $270, citing an 11.1% increase. This target suggests an 11.6% upside from the Nov 2 close of $268.89. Other recent analyst price targets for Tenet range from $304 to $342.

Original reporting
Published Nov 3, 2026, 1:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 1:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Keybanc maintains Tenet Healthcare at Overweight, raises price target to $300 from $270 — source image
Decision brief

The 30-second read

$THCBullishLow
01

Why it matters

The upgrade signals confidence in Tenet's future performance, which may attract new buyers and support the stock price.

02

Market read

Analyst target raise provides a modest trading signal for THC, potentially prompting short-term buying.

03

What to watch

Potential regulatory or reimbursement risks that are not reflected in the new target.

Relevance 5/10Novelty 5/10Timing: today

Background

Tenet Healthcare (THC) is a U.S. hospital operator. Analyst price target changes are a common catalyst for short-term price moves.

Company-level read

Ticker impact

$THCBullishMedium confidence
Context

Keybanc raised its price target on Tenet Healthcare to $300 from $270, indicating a bullish outlook.

Expected impact

potential upward pressure as the market incorporates the new target

Evidence & confidence

The price target increase suggests improved expectations for earnings or growth, which can attract buying interest.

Market effects

May boost sentiment in the healthcare services sector.

Limited to U.S. markets where Tenet trades.

Minimal global impact.

Counterpoint

The target raise could be premature if underlying earnings growth does not materialize.

Key entities

  • Keybanc

    Equity research firm that issued the price target raise.

  • Tenet Healthcare

    U.S.-based healthcare services provider.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.